Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 28, 2007. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Purchased: 1,375,000 Ordinary shares of 25 pence each.
- Purchase Date: June 28, 2007.
- Purchase Price: 1,306.803 pence per share.
- Treasury Holdings Post-Purchase: 325,549,158 shares (representing 5.72% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,695,329,619 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 1,375,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 325,549,158. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,695,329,619) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (325,549,158) and its percentage of voting rights (5.72%).
- Review the specific purchase price (1,306.803p) to assess the cost basis of the repurchased shares.